opioid

View All

Opioid Withdrawal Syndrome
Opioid Withdrawal Syndrome Pipeline: What lies in the future for those facing withdrawal symptoms

Every time an opioid therapy is in the option for any patient to overcome the pain due to some chronic ailment, the risk of opioid abuse, misuse, or dependence always lingers at the back of mind. After termination of the opioids, the patient finds it difficult to stop the use of drugs and begins to crave for it. Th...

Find More

Opioid Withdrawal Syndrome
Opioid Withdrawal Syndrome: What happens when a person withdraws from Opiates

The year 2016, around 48.5 million Americans older than 12 years, reported to be actively abusing prescription opioids or involved in illicit drug use, says CDC drug surveillance report. The toll has been increasing and is almost impossible to ignore. It is disheartening to note that between the period between 1999...

Find More

EMA to relocate to Amsterdam; Roche’s prospects; Amgen’s Humira Biosimilar delayed; Purdue’s opioid lawsuit

EMA to relocate to Amsterdam by March 2019 Results of the Monday's vote for the European Medicines Agency relocation led to the emergence of Amsterdam as the new headquarters, beating the other finalists Milan and Copenhagen. Nineteen European Union member states submitted proposals for the EMA headquarters, and Mil...

Find More

Tesaro’s Zejula; Mylan on EpiPen; Ohio sues drugmakers; ATUM, Horizon Discovery Announce deal

Tesaro and its new med Zejula are on the block, but bidders aren't rushing in Just ahead of the year’s biggest download of cancer data, the maker of a closely watched drug has put itself up for sale, according to The Wall Street Journal. That’s Tesaro, whose PARP inhibitor Zejula won FDA approval in March. That med ...

Find More